ClinicalTrials.gg
RecruitingNCT07234591Updated Nov 18, 2025

A Study to Evaluate Effectiveness and Safety of a TYK2 Inhibitor in Subjects With Moderate to Severe Plaque Psoriasis

An interventional study of Tyk2 inhibitor and Placebo in Plaque Psoriasis and Moderate to Severe Plaque Psoriasis, sponsored by Usynova Pharmaceuticals Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-11-18.

Sponsored by Usynova Pharmaceuticals Ltd. · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Apr 2026, 6 months ago, but the record still lists the study as recruiting.
  • Started Oct 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 206 studies in Psoriasis with a site in China — 56 open to participants now, 66 under way, 22 of them phase 3. Psoriasis · China.

Planned enrollment
102nd of 182
140 · median 171
Started
2025
with 35 others
No phase
20 of 206
7 open now
Primary completion
2026-04
later than 19 of 65 live
Registered
174th of 206
by date

Among the 206 studies in Psoriasis with a site in China, this one is the 102nd largest by planned enrollment of the 182 interventional ones that give a count, is one of 36 that started in 2025, is one of 20 with no phase, reaches primary completion later than 19 of the 65 other live ones, and was the 174th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

56 of the 206 studies in Psoriasis with a site in China are open now. Recruiting first, the newest first:

50 more — sign in →

All 56 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies in Psoriasis with a site in China, or all of them as a file.
02

Study summary

A Study to evaluate efficacy and safety in subjects with moderate to severe Plaque Psoriasis treated with a TYK2 Inhibitor for 12 weeks

03

Conditions studied

  • Plaque Psoriasis
  • Moderate to Severe Plaque Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female, ages 18 to 70 years
  • Body weight >40 kg, (BMI) of 18 to 40 kg/m2
  • Clinical diagnosis of plaque psoriasis for ≥6 months before the Baseline visit
  • Women of (WOCBP) and males who are sexucally active must agree to follow instructions for method(s) of .

Exclusion criteria

Exclusion Criteria:

  • Diagnosed with non-plaque psoriasis
  • Previously received tyrosine kinase 2 (TYK2) inhibitors
  • Previously received other psoriasis treatments such as biological agents, immunoregulators, or hormonal drugs within a specific period before administration, and the investigator deems it may affect the immunity of the subjects
  • Has participated in any clinical trials within 30 days or 5 half-lives of the drug before the first administration, or currently undergoing visits for other clinical trials;
  • Has history of chronic disease that may affect the study, or acute or chronic severe infectious diseases, such as a history of active or inadequately treated latent tuberculosis infection, severe bone or joint infections within 6 months before screening, and other acute infectious diseases.
  • Has known or suspected skin or systemic diseases other than psoriasis and psoriatic arthritis;
  • Other conditions that the investigator deems unsuitable for participation in this study.

Other protocol defined inclusion/exclusion criteria could apply

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
140 participants (estimated)

Study arms

  • Experimental
    dose level 1

    Drug: Tyk2 inhibitor

  • Experimental
    dose level 2

    Drug: Tyk2 inhibitor

  • Experimental
    dose level 3

    Drug: Tyk2 inhibitor

  • Placebo comparator
    placebo

    Drug: Placebo

Interventions

  • DrugTyk2 inhibitor

    Specific dose of Tyk2 inhibitor on specific days

  • DrugPlacebo

    Specified dose of Placebo on specified days.

06

What researchers measure

Primary outcomes

  1. The Percentage of Participants Experiencing a 75% Improvement (Reduction From Baseline) in PASI Score (PASI-75 Response Rate) on Week 12

    Time frame: Baseline to Week 12

Secondary outcomes

  1. Percentage of Participants With PASI-90, PASI-100 on Week 12

    Time frame: Baseline to Week 12

  2. Percentage of Participants on Week 12 With sPGA Score of 0 or 1 (sPGA0/1 Response Rate)

    Time frame: Baseline to Week 12

  3. Change From Baseline in DLQI Scores to Week 12

    Time frame: Baseline to Week 12

  4. Change From Baseline in BSA to Week 12

    Time frame: Baseline to Week 12

  5. Number of Participants With Adverse Events

    Time frame: From enrollment to Day 112

  6. Mean steady-state plasma concentration of the drug (Cav,ss)

    Time frame: Day 1, Day 8, Day 15, Day 29, Day 57, Day 84

  7. Steady-state trough plasma concentration of the drug (Ctrough, ss)

    Time frame: Day 1, Day 8, Day 15, Day 29, Day 57, Day 84

  8. The area under the steady-state blood drug concentration-time curve (AUCss)

    Time frame: Day 1, Day 8, Day 15, Day 29, Day 57, Day 84

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Apr 2026, 6 months after the start.

Of 134 interventional studies with no phase under Psoriasis, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 38. This study's planned 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2025
First posted
Nov 18, 2025
StartActual
Oct 21, 2025
Primary completionEst.
Apr 30, 2026
CompletionEst.
May 30, 2026
Last update
Nov 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07234591
Lead sponsor
Usynova Pharmaceuticals Ltd.
Responsible party
Sponsor
First posted
Nov 18, 2025
Start date
Oct 21, 2025
Primary completion
Apr 30, 2026 (estimated)
Completion
May 30, 2026 (estimated)
Last update
Nov 18, 2025

Study contacts

Yang Zhang
Contact
yang_zhang@usynova.com
+8613636393195

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion